2023
Delta‐9‐tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: A within‐subject, randomized, placebo‐controlled laboratory study
De Aquino J, Meyerovich J, Xie C, Ranganathan M, Compton P, Pittman B, Rogan M, Sofuoglu M. Delta‐9‐tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: A within‐subject, randomized, placebo‐controlled laboratory study. Addiction Biology 2023, 28: e13317. PMID: 37644897, PMCID: PMC10468603, DOI: 10.1111/adb.13317.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid agonist therapyAgonist therapyMethadone dosesMethadone therapyPain sensitivityUse disordersPlacebo-controlled laboratory studySynergistic antinociceptive effectCognitive adverse effectsSingle oral dosesRisk-benefit profilePain sensitivity measuresCannabinoid receptor systemAntinociceptive effectTHC doseOral dosesOpioid agonistsAcute effectsCannabinoid agonistsPreclinical studiesAbuse potentialOpioid crisisTherapyReceptor systemIntegrating cognitive bias modification for pain and opioid cues into medication for opioid use disorder clinical care: Feasibility, acceptability, and preliminary results
MacLean R, Heapy A, Waters A, Wolkowicz N, Szollosy S, Meyerovich J, Sofuoglu M. Integrating cognitive bias modification for pain and opioid cues into medication for opioid use disorder clinical care: Feasibility, acceptability, and preliminary results. Drug And Alcohol Dependence 2023, 246: 109857. PMID: 37004461, PMCID: PMC10189744, DOI: 10.1016/j.drugalcdep.2023.109857.Peer-Reviewed Original ResearchConceptsTrial-level bias scoresOpioid cuesAB taskCognitive bias modification taskAttentional bias taskCognitive bias modificationComputer-based tasksPreliminary efficacyOpioid use disorderCurrent studyBias modificationBias taskBias scoresModification tasksCBM groupCBM tasksChronic painAcceptability measuresControl conditionTaskUse disordersClinical careCuesTime interactionParticipantsOpioid Use Disorder With Chronic Pain Increases Disease Burden and Service Use
MacLean RR, Sofuoglu M, Stefanovics E, Rosenheck R. Opioid Use Disorder With Chronic Pain Increases Disease Burden and Service Use. Psychological Services 2023, 20: 157-165. PMID: 34968125, PMCID: PMC9358616, DOI: 10.1037/ser0000607.Peer-Reviewed Original ResearchConceptsOpioid use disorderChronic painMental health diagnosesService useUse disordersHealth AdministrationConcurrent opioid use disorderHealth diagnosisOngoing opioid epidemicOutpatient service useVeterans Health AdministrationMental health disordersSubstance use diagnosesSingle disorder groupsClinical service useOpioid prescriptionsAdditional comorbiditiesMultinomial regression analysisDisease burdenMedication fillsOpioid epidemicPrescription opiatesMedical conditionsMedical disordersUse diagnosesThreshold for the Pleasurable Effects of Nicotine Are Lower Than Its Reinforcing Effects During Self-Administration
MacLean RR, Eid T, Parida S, Gueorguieva R, DeVito EE, Sofuoglu M. Threshold for the Pleasurable Effects of Nicotine Are Lower Than Its Reinforcing Effects During Self-Administration. Experimental And Clinical Psychopharmacology 2023, 31: 37-45. PMID: 35254839, PMCID: PMC9448824, DOI: 10.1037/pha0000556.Peer-Reviewed Original ResearchConceptsNicotine metabolite ratioDose of nicotineNicotine reinforcementSubjective effectsDiscriminative stimulus effectsHeart rate increaseDoses of nicotineSelf-administration procedureSubjective positive effectsDaily smokersBaseline cravingIntravenous nicotineOvernight abstinenceCigarette cravingDrug effectsMetabolite ratiosStimulus effectsSecondary analysisPlaceboSelf-AdministrationNicotine choiceTobacco productsNicotinePleasurable effectsYoung adultsExamining racial differences in smoking outcomes among smokers enrolled in an intravenous nicotine infusion study
Schwartz E, Palmisano A, Gueorguieva R, DeVito E, Sofuoglu M. Examining racial differences in smoking outcomes among smokers enrolled in an intravenous nicotine infusion study. Addictive Behaviors 2023, 140: 107615. PMID: 36640662, PMCID: PMC9911383, DOI: 10.1016/j.addbeh.2023.107615.Peer-Reviewed Original ResearchConceptsSmoking-related illnessesNegative drug effectsNicotine clearanceOvernight abstinenceNicotine infusionDrug effectsMentholated cigarettesWhite individualsBlack individualsAcute pharmacologic effectsSmoking-related morbiditySmoking-related diseasesAdministration of nicotineSmoking-related outcomesSubjective drug effectsShort-term abstinenceLower ratesTrend level differenceLarge racial disparitiesNicotine administrationNicotine dosesTrend-level significancePharmacologic effectsTreatment strategiesOutcome measures
2022
Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: A systematic review of observational and experimental human studies
De Aquino J, Bahji A, Gómez O, Sofuoglu M. Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: A systematic review of observational and experimental human studies. Drug And Alcohol Dependence 2022, 241: 109702. PMID: 36434879, PMCID: PMC9772106, DOI: 10.1016/j.drugalcdep.2022.109702.Peer-Reviewed Original ResearchConceptsOpioid withdrawalObservational studySystematic reviewDelta-9-tetrahydrocannabinol administrationPlacebo-controlled clinical trialCannabis useNon-opioid therapeuticsPotential of cannabinoidsDose of opioidsOpioid withdrawal symptomsOpioid use disorderNarrow therapeutic windowExperimental human studiesDose-dependent increaseMain psychoactive constituentPatient characteristicsWithdrawal symptomsClinical trialsPharmacological factorsStudy qualityTherapeutic windowTherapeutic benefitUse disordersHuman studiesAbuse liabilityEffect of progesterone administration in male and female smokers on nicotine withdrawal and neural response to smoking cues: role of progesterone conversion to allopregnanolone
Novick AM, Duffy KA, Johnson RL, Sammel MD, Cao W, Strasser AA, Sofuoglu M, Kuzma A, Loughead J, Morrow AL, Epperson CN. Effect of progesterone administration in male and female smokers on nicotine withdrawal and neural response to smoking cues: role of progesterone conversion to allopregnanolone. Biology Of Sex Differences 2022, 13: 60. PMID: 36274158, PMCID: PMC9590190, DOI: 10.1186/s13293-022-00472-w.Peer-Reviewed Original ResearchConceptsTobacco use disorderProgesterone ratioConversion of progesteroneNicotine withdrawalSmoking cuesTherapeutic effectPlacebo-controlled crossover studySmoking-related outcomesNeural responsesSex-dependent effectsGreater therapeutic benefitDays of abstinenceCrossover studyFemale smokersProgesterone administrationNeurosteroid allopregnanoloneWithdrawal symptomsNicotine effectsWithdrawal severityAllopregnanoloneTherapeutic benefitUse disordersSmoking urgesProgesteroneProgesterone conversionProgesterone Increases Nicotine Withdrawal and Anxiety in Male but Not Female Smokers During Brief Abstinence
Novick AM, Duffy KA, Johnson RL, Sammel MD, Cao W, Strasser AA, Sofuoglu M, Kuzma A, Loughead J, Epperson CN. Progesterone Increases Nicotine Withdrawal and Anxiety in Male but Not Female Smokers During Brief Abstinence. Nicotine & Tobacco Research 2022, 24: 1898-1905. PMID: 35713950, PMCID: PMC9653080, DOI: 10.1093/ntr/ntac146.Peer-Reviewed Original ResearchConceptsBrief abstinenceNegative affectNicotine withdrawalNicotine use disorderUse disordersFemale smokersNeural measuresFinal drug administrationSmoking cuesSmoking-related outcomesNeural responsesEffect of progesteroneSmoking urgesMood statesSex-dependent effectsSmoking outcomesNicotine effectsDrug AdministrationAbstinence periodSubjective effectsNicotine dependenceAbstinenceMain effectSignificant sexPlacebo-controlled crossover studyDevelopment of pulsed intravenous nicotine infusions as a model for inhaled nicotine in humans
De Aquino JP, DeVito EE, Xie C, Meyerovich J, Parida S, Gueorguieva R, Sofuoglu M. Development of pulsed intravenous nicotine infusions as a model for inhaled nicotine in humans. Psychopharmacology 2022, 239: 2809-2818. PMID: 35554617, DOI: 10.1007/s00213-022-06162-0.Peer-Reviewed Original ResearchImpact of delivery rate on the acute response to intravenous nicotine: A human laboratory study with implications for regulatory science
De Aquino JP, MacLean RR, Gueorguieva R, DeVito EE, Eid T, Sofuoglu M. Impact of delivery rate on the acute response to intravenous nicotine: A human laboratory study with implications for regulatory science. Addiction Biology 2022, 27: e13161. PMID: 35229960, PMCID: PMC8903077, DOI: 10.1111/adb.13161.Peer-Reviewed Original ResearchConceptsAbuse potentialPositive subjective drug effectsSubjective drug effectsHuman laboratory studiesPositive subjective effectsAttention functionSmoking urgesOvernight abstinencePotential therapeutic effectsEffects of nicotineHeart rate increaseDelivery rateDependent smokersExperimental sessionsSubjective effectsNicotine dependenceIntravenous nicotineBlood pressureSaline infusionAcute effectsTherapeutic effectHeart rateDrug effectsAcute responseCrossover design
2021
Opioid-induced analgesia among persons with opioid use disorder receiving methadone or buprenorphine: A systematic review of experimental pain studies
De Aquino JP, Parida S, Avila-Quintero VJ, Flores J, Compton P, Hickey T, Gómez O, Sofuoglu M. Opioid-induced analgesia among persons with opioid use disorder receiving methadone or buprenorphine: A systematic review of experimental pain studies. Drug And Alcohol Dependence 2021, 228: 109097. PMID: 34601272, PMCID: PMC8595687, DOI: 10.1016/j.drugalcdep.2021.109097.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOpioid use disorderExperimental pain studiesAbuse potentialRespiratory depressionAcute painPain studiesUse disordersSystematic reviewGreater abuse potentialHigh-potency opioidsMethadone-maintained personsSignificant pain reliefRespiratory depressant effectsHigh-potency compoundsOpioid naïveAgonist therapyOpioid dosesPain reliefAnalgesic effectSevere painDepressant effectAdditional dosesStudy qualityHealthy personsThe Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder
De Aquino JP, Parida S, Sofuoglu M. The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder. Clinical Drug Investigation 2021, 41: 425-436. PMID: 33818748, PMCID: PMC8020374, DOI: 10.1007/s40261-021-01032-7.Peer-Reviewed Original ResearchConceptsUnique pharmacological profileOpioid use disorderOpioid withdrawalPotential dose-dependent effectsPlacebo-controlled clinical trialLong-term treatment outcomesFull opioid agonistsStandard induction regimensOpen-label studyFirst-line pharmacotherapySchedule of administrationMu-opioid receptorsAvailability of buprenorphineDose-dependent effectFuture translational researchInduction regimensOpioid taperOpioid toneFirst doseClinical outcomesClinical evidenceOpioid agonistsBuprenorphine formulationsDaily dosesClinical trialsThreshold dose for intravenous nicotine self-administration in young adult non-dependent smokers
MacLean RR, DeVito EE, Eid T, Parida S, Gueorguieva R, Sofuoglu M. Threshold dose for intravenous nicotine self-administration in young adult non-dependent smokers. Psychopharmacology 2021, 238: 2083-2090. PMID: 33796907, PMCID: PMC8715498, DOI: 10.1007/s00213-021-05833-8.Peer-Reviewed Original ResearchConceptsDose of nicotineNicotine reinforcementHigh doseSubjective effectsHuman laboratory studiesYoung adult smokersNicotine self-administration modelNon-dependent smokersOvernight nicotine abstinenceEffects modelSelf-administration modelSelf-administration procedureNicotine doseAdult smokersMethodsYoung adultsObjectivesThe current studyNicotine abstinenceNicotine addictionHigh dosesLow dosesPlaceboThreshold doseReinforcement thresholdTobacco productsDose
2019
Randomized placebo-controlled trial of galantamine in individuals with cocaine use disorder
DeVito EE, Carroll KM, Babuscio T, Nich C, Sofuoglu M. Randomized placebo-controlled trial of galantamine in individuals with cocaine use disorder. Journal Of Substance Use And Addiction Treatment 2019, 107: 29-37. PMID: 31757262, PMCID: PMC6918721, DOI: 10.1016/j.jsat.2019.08.009.Peer-Reviewed Original ResearchConceptsCocaine use disorderSignificant treatment group differencesUse disordersEfficacy of galantamineTreatment-seeking cocaine usersCurrent cocaine use disordersGroup differencesCocaine use outcomesSample of individualsTreatment group differencesComorbid opioid use disorderMethadone-maintained individualsMemory capacityAbstinent individualsCocaine useCognitive improvementCognitive outcomesCocaine use reductionCognitive functionUse outcomesCocaine usersGalantamine groupIndividualsDisordersInitial promiseDouble‐Blind Placebo‐Controlled Trial of Galantamine for Methadone‐Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use
Carroll KM, DeVito EE, Yip SW, Nich C, Sofuoglu M. Double‐Blind Placebo‐Controlled Trial of Galantamine for Methadone‐Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use. American Journal On Addictions 2019, 28: 238-245. PMID: 31165574, PMCID: PMC9078084, DOI: 10.1111/ajad.12904.Peer-Reviewed Original ResearchConceptsMethadone-maintained individualsOpioid useSecondary analysisMultiple drugsConcurrent cocaine dependenceTrial of galantaminePlacebo-controlled trialDouble-blind placeboIllicit opioid useRandomized clinical trialsCocaine use disorderGalantamine's effectFuture trialsClinical trialsUrine specimenUrine specimensUse disordersOpioidsCholinesterase inhibitorsMaintenance settingCocaine useCocaine dependencePlaceboConcurrent useGalantamine
2018
Minocycline does not affect experimental pain or addiction-related outcomes in opioid maintained patients
Arout CA, Waters AJ, MacLean RR, Compton P, Sofuoglu M. Minocycline does not affect experimental pain or addiction-related outcomes in opioid maintained patients. Psychopharmacology 2018, 236: 2857-2866. PMID: 30564869, PMCID: PMC6581631, DOI: 10.1007/s00213-018-5146-7.Peer-Reviewed Original ResearchConceptsOpioid-induced hyperalgesiaCold pressor testOpioid use disorderSerum cytokinesPain thresholdUse disordersAddiction-related outcomesProinflammatory serum cytokinesActivation of microgliaSeverity of painEcological momentary assessmentEnd of treatmentHuman laboratory studiesTest sessionsOpioid cravingMinocycline treatmentOpioid toleranceAgonist treatmentPain sensitivityVisit 1Minocycline effectsPressor testExperimental painPreclinical studiesGo/No-Go taskThe Cholinergic System as a Treatment Target for Opioid Use Disorder
Jensen KP, DeVito EE, Yip S, Carroll KM, Sofuoglu M. The Cholinergic System as a Treatment Target for Opioid Use Disorder. CNS Drugs 2018, 32: 981-996. PMID: 30259415, PMCID: PMC6314885, DOI: 10.1007/s40263-018-0572-y.Peer-Reviewed Original ResearchConceptsCholinergic systemUse disordersTreatment targetsOpioid use disorder epidemicCentral nervous system functionTreatment of OUDEffects of acetylcholineOpioid use disorderTobacco use disorderNervous system functionOpioid medicationsDegrade acetylcholineCurrent treatmentOpioid overdosesPreclinical studiesMedicationsAcetylcholineCholinesterase inhibitorsAlzheimer's diseaseNew treatmentsAccidental deathGlobal healthTreatmentOUDDisease
2017
Inhalation of Alcohol Vapor: Measurement and Implications
MacLean RR, Valentine GW, Jatlow PI, Sofuoglu M. Inhalation of Alcohol Vapor: Measurement and Implications. Alcohol Clinical And Experimental Research 2017, 41: 238-250. PMID: 28054395, PMCID: PMC6143144, DOI: 10.1111/acer.13291.Peer-Reviewed Original ResearchConceptsAlcohol inhalationAlcohol consumptionAcute alcohol exposureElevated blood alcohol concentrationsRoute of administrationOral alcohol consumptionFirst-pass metabolismAlcohol use disorderPublic health concernMeasurement of biomarkersBlood alcohol concentrationRisk of addictionPharmacodynamic profileAlcohol exposureArterial circulationOccupational exposureMeasurable biomarkersPharmacological effectsUse disordersInhalationE-cigarettesHealth concernSubjective effectsRisk of problemsGoogle Scholar
2015
Intravenous Nicotine Self-Administration in Smokers: Dose–Response Function and Sex Differences
Jensen KP, DeVito EE, Valentine G, Gueorguieva R, Sofuoglu M. Intravenous Nicotine Self-Administration in Smokers: Dose–Response Function and Sex Differences. Neuropsychopharmacology 2015, 41: 2034-2040. PMID: 26717881, PMCID: PMC4908640, DOI: 10.1038/npp.2015.373.Peer-Reviewed Original ResearchConceptsBlood pressureHeart rateFemale smokersRandomized double-blind crossover designDouble-blind crossover designSubjective effectsTobacco-dependent subjectsSex differencesDiastolic blood pressureIntravenous Nicotine Self-AdministrationSelf-administration ratesNicotine Self-AdministrationDose-response functionNicotine dosesNicotine doseTobacco dependenceIntravenous nicotineCrossover designSelf-AdministrationReinforcement thresholdSmokersInfusionNicotineForced-choice trialsAversive responsesThe effects of alcohol-containing e-cigarettes on young adult smokers
Valentine GW, Jatlow PI, Coffman M, Nadim H, Gueorguieva R, Sofuoglu M. The effects of alcohol-containing e-cigarettes on young adult smokers. Drug And Alcohol Dependence 2015, 159: 272-276. PMID: 26778759, PMCID: PMC5171208, DOI: 10.1016/j.drugalcdep.2015.12.011.Peer-Reviewed Original ResearchConceptsSubjective drug effectsE-cigarettesDrug effectsAlcohol metabolitesPlasma alcohol levelsUrine ethyl glucuronideLong-term health risksYoung adult smokersAlcohol conditionE-liquidsAcute safetyAdult smokersNicotine intakeAcute changesSafety dataNicotine addictionCrossover designBiochemical measuresAlcohol levelsPsychomotor performanceElectronic cigarettesDexterity testVulnerable populationsEthyl glucuronideMotor performance